余瑶
性别:女
学历:博士研究生
Email: yuyao1021@163.com
联系方式:15667082329
教育背景:
2013.09-2018.03 西安交通大学 工学博士;生物医学工程;生物材料与纳米载体方向
2016.09-2017.09 约翰霍普金斯大学 联合培养博士,生物医学工程
2009.09-2013.07 西安交通大学 工学学士;生物医学工程(本硕连读专业)
2010.09-2011.01 台湾义守大学 交流学生,生物科技系
工作经历:
2018.04-2019.06 武汉大学人民医院 助理研究员
2019.07-至今 bbin官方平台 讲师
研究方向:
纳米药物载体;造影剂及其成像设备
论文清单:
(1) Yu, Yao; Cai, Jingjing; She, Zhigang; Li, Hongliang (*), Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases, Advanced Science, 2019.2.20, 6(4): 1801585. JCR一区,五年IF: 12.4
(2) Yu, Yao; Wu, Youshen; Liu, Jiajun; Liu, Yiming; Wu, Daocheng (*), Highly efficient dual-modal phosphorescence/computed tomography bioprobes based on an iridium complex and AuNP polyiohexol composite nanoparticles., Nanoscale, 2017.7.13, 9(27): 9447~9456. JCR一区,五年IF: 7.713
(3) Yu, Yao; Wu, Youshen; Liu, Jiajun; Li, Ke; Wu, Daocheng (*), Metabolizable dopamine-coated gold nanoparticle aggregates: preparation, characteristics, computed tomography imaging, acute toxicity, and metabolism in vivo, Journal of Materials Chemistry B, 2016, 4(6): 1090~1099. JCR一区,五年IF: 4.787
(4) Yu, Yao; Wu, Youshen; Liu, Jiajun; Zhan, Yonghua; Wu, Daocheng (*), Ultrasmall dopamine-coated nanogolds: preparation, characteristics, and CT imaging, Journal of Experimental Nanoscience, 2016, 11: 1~11. JCR三区,五年IF: 1.089
(5) Chen, Z; Yu, Yao; Cai, Jingjing; Li, Hongliang (*), Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease, Trends in Endocrinology & Metabolism, 2019, https://doi.org/10.1016/j.tem.2019.08.006. JCR一区, IF: 9.777
(6) Liu, Jiajun; Wu, Youshen; Yu, Yao; Li, Ke; Ji, Yuanyuan; Wu, Daocheng (*), Quantitative ratiometric phosphorescence hypoxia-sensing nanoprobes based on quantum dots/Ir(III) glycerol monoolein cubic-phase nanoparticles, Biosensors& Bioelectronics, 2017, 98: 119-125. JCR一区,IF: 7.29
基金项目:
1.中央高校自主创新基金/武汉大学自主科研项目,IRF2在肥胖中的作用与机制研究,6万元,201901-202012,2042019kf0068,主持,在研。
2.国家自然科学基金重点项目,基于响应性高分子动态氢键网络的糖蛋白组学富集分离新材料(项目负责人:孙涛垒,分解经费20万元),20151j0184,参与,在研。
3.企业委托,Sa-1和Sa-2药物疾病模型横向委托开发合同(项目负责人:高冠斌),分解经费10万元),20192h0118,参与,在研。